Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for Tepezza (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration

DUBLIN--(BUSINESS WIRE)--Apr. 14, 2023-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Indications and Usage section of the Tepezza label to specify its use for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news